Further studies are needed to address whether the favorable association is site specific, as null associations are likely to be observed in some hormone-related cancers, such as endometrial cancer [31], ovarian cancer [32] and estrogen-receptor–positive breast cancer [20]. This evidence concerns the gene ESR1 and breast carcinoma.